NEUROIMAGING, NEUROPSYCHIATRY, AND COGNITIVE FUNCTIONING

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 1.我们对神经精神疾病中出现的细微认知功能障碍感兴趣。越来越多的证据表明，在与上述疾病相关的坦率的精神和神经症状出现之前，认知功能可能会发生变化[1，2，3，4]，如果是这样的话，这些可能是病理过程的第一个表现。到目前为止，认知障碍的性质还没有得到很好的描述，随后也没有得到很好的理解。总的来说，受影响的功能似乎是注意力、记忆力和“执行”功能(决策能力)[5，6，7，8]。 在这个方案中，我们将把我们的调查范围限制在上面列出的大类中的两个特定子集：内隐记忆/学习，以及注意的一个方面，持续注意(有时被称为警觉)。在未来，我们打算谨慎地扩大我们的关注点，将工作记忆、执行功能和可能的视觉注意方面包括在内。我们正在开发这些fMRI范例，并将在适当的时候引入它们。 我们对研究亨廷顿病(HD)、帕金森病(PD)、情感性疾病(即抑郁症)和精神分裂症的受试者很感兴趣，这是该方案最早的迭代中所描述的。我们希望包括一组具有阿尔茨海默病(AD)遗传风险的受试者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. 1. We are interested in subtle cognitive dysfunction that occurs in neuropsychiatric illness. There is mounting evidence that prior to the onset of frank psychiatric and neurologic symptoms associated with the illnesses in question, there may be changes in cognitive function [1,2,3,4], if so, these may represent the first manifestations of pathologic processes. The nature of the cognitive impairments are as yet poorly characterized and subsequently not well understood. In gross terms the functions affected appear to be attention, memory, and "executive" function (decision making abilities) [5,6,7,8]. In this protocol we will limit our area of inquiry to two specific subsets of the broad categories listed above: implicit memory/learning, and one aspect of attention, sustained attention (sometimes referred to as vigilance). In the future we intend to cautiously broaden our focus to include aspects of working memory, executive function and likely visual attention. We have these fMRI paradigms in development and will introduce them when appropriate. We are interested, as described in the earliest of iterations of this protocol in studying subjects with Huntington's Disease (HD), Parkinson's Disease (PD), Affective illness (i.e. Major Depression) and Schizophrenia. We would like to include a cohort of subjects genetically at risk for Alzheimer's Disease (AD).